Montemaggi P, Costamagna G, Dobelbower R R, Cellini N, Morganti A G, Mutignani M, Perri V, Brizi G, Marano P
Istituto di Radiologia, Universitá Cattolica del Sacro Cuore, Roma.
Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):437-43. doi: 10.1016/0360-3016(95)00518-4.
A new method of palliation of malignant obstructive jaundice is presented.
Twelve patients with carcinoma of the extrahepatic bile ducts (EHBD-five patients) or pancreatic head (PH-seven patients) received radiation therapy between 1988 and 1991. Percutaneous transhepatic biliary drainage was performed in four EHBD patients and an endoprosthesis was placed during endoscopic retrograde cholangiopancreatography (ERCP) in the other eight patients. All 12 received intraluminal brachytherapy (ILBT): 20-50 Gy calculated at 1 cm from the Iridium-192 (192Ir) wire. In four PH patients the source was placed in the duct of Wirsung; in the other eight patients ILBT was performed via the common bile duct. Five of the seven PH patients and one of the five EHBD patients received External Beam Radiation Therapy (EBRT): 26-50 Gy, alone or with concomitant 5-Fluorouracil (5-FU).
Cholangitis occurred in six patients. Three PH patients treated with EBRT+ILBT developed gastrointestinal toxicities. With a minimum follow-up of 18 months, median survival times were 14 months (EHBD) and 11.5 months (PH); one of the seven PH patients is alive (29 months) and two of the EHBD patients are alive (18 and 43 months). All patients had satisfactory control of jaundice.
The results in the EHBD patients suggest that the addition of ILBT after biliary drainage prolongs survival. Further experience is necessary to determine whether ILBT in the common bile duct and/or in the duct of Wirsung may be, in PH patients, an alternative boost technique to Interstitial Brachy-therapy (IBT) or Intraoperative Electron Beam Radiation Therapy (IOEBRT).
介绍一种缓解恶性梗阻性黄疸的新方法。
1988年至1991年间,12例肝外胆管癌(EHBD,5例)或胰头癌(PH,7例)患者接受了放射治疗。4例EHBD患者接受了经皮肝穿刺胆道引流,另外8例患者在内镜逆行胰胆管造影(ERCP)期间放置了内支架。所有12例患者均接受了腔内近距离放射治疗(ILBT):以距铱-192(192Ir)导线1 cm处计算,剂量为20 - 50 Gy。4例PH患者的放射源置于胰管;另外8例患者通过胆总管进行ILBT。7例PH患者中的5例和5例EHBD患者中的1例接受了外照射放疗(EBRT):26 - 50 Gy,单独使用或与5-氟尿嘧啶(5-FU)联合使用。
6例患者发生胆管炎。3例接受EBRT + ILBT治疗的PH患者出现胃肠道毒性反应。随访至少18个月,EHBD患者的中位生存时间为14个月,PH患者为11.5个月;7例PH患者中有1例存活(29个月),5例EHBD患者中有2例存活(18个月和43个月)。所有患者的黄疸均得到满意控制。
EHBD患者的结果表明,胆道引流后加用ILBT可延长生存期。需要进一步的经验来确定,在PH患者中,胆总管和/或胰管内的ILBT是否可作为间质近距离放射治疗(IBT)或术中电子束放射治疗(IOEBRT)的替代增强技术。